Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 17, 2025

Glycomine secures $115m funding for Phase IIb trial of rare disease drug

US-based biotechnology company Glycomine has secured $115m in Series C funding to progress the mannose-1-phosphate replacement therapy GLM101 into a randomised Phase IIb trial.

PMM2-CDG stems from a genetic mutation in the PMM2. Credit: Braňo on Unsplash.